杜氏肌肉营养不良 (DMD) 药物市场、机会、成长动力、产业趋势分析与预测，2024-2032 年

Duchenne Muscular Dystrophy (DMD) Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月10日 | 出版商:

Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在政府和监管支持的不断加强以及研发力度的加强的带动下，杜氏肌肉营养不良症药物市场规模预计从 2024 年到 2032 年将以 11.6% 的复合年增长率扩大。各国政府正在透过资金和监管批准加快杜氏肌肉营养不良症 (DMD) 新疗法的上市。研究人员正在创新疗法并增强现有药物，以满足 DMD 患者的需求。例如，2024 年 3 月，美国 FDA 批准 Duvyzat（givinostat），一种治疗 DMD 的口服药物，适用于 6 岁及以上患者。

整个市场按药物类型、给药途径和地区划分。

根据药物类型，由于迫切需要解决该疾病的遗传根源，预计从 2024 年到 2032 年，来自基因治疗领域的 DMD 药物市场价值将大幅增长。基因疗法旨在纠正或替换有缺陷的肌肉营养不良蛋白基因，该基因在肌肉退化中至关重要。研究人员直接将功能性肌肉营养不良蛋白基因拷贝传递到肌肉细胞，利用先进的载体实现最佳的基因转移和表现。

由于对有效治疗的需求不断增长，预计到 2032 年，杜氏肌肉营养不良症药物行业的注射给药途径将以复合年增长率大幅增长。注射剂可直接进入肌肉组织或全身循环，增强药物吸收和疗效。此外，注射技术的进步正在为有效的递送系统铺平道路，包括缓释製剂和新颖的递送方法。

从地区来看，由于製药公司、研究机构和生技公司之间的合作不断增加，预计亚太地区杜氏肌肉营养不良症药物市场规模在 2024 年至 2032 年间将出现显着的复合年增长率。这些合作伙伴关係涵盖临床试验、药物开发和监管支持，旨在增强该地区 DMD 患者的治疗选择和结果。

产业生态系统分析
产业影响力
- 成长动力
  - DMD 疾病负担不断增加
  - 提高对 DMD 的认识和诊断
  - 不断增加的研究经费和活动
  - 基因研究的进展
- 产业陷阱与挑战
  - 治疗费用高
成长潜力分析
管道分析
监管环境
专利分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按药物类型，2021 - 2032

主要趋势
外显子跳跃药物
皮质类固醇
基因治疗
其他药物类型

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

主要趋势
口服
可注射

第 7 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 8 章：公司简介

Aurobindo Pharma
Capricor Therapeutics, Inc.
Catalyst Pharmaceuticals Inc
EspeRare Foundation
FibroGen, Inc.
Italfarmaco S.p.A
NS Pharma
PTC Therapeutics, Inc.
Santhera Pharmaceuticals
Sarepta Therapeutics, Inc.
Solid Biosciences Inc.

简介目录

Product Code: 10182

Duchenne Muscular Dystrophy Drugs Market size is projected to expand at an 11.6% CAGR from 2024 to 2032, led by the rising government and regulatory support along with increasing R and D efforts. Governments are expediting the availability of new treatments for duchenne muscular dystrophy (DMD) through funding and regulatory approvals. Researchers are innovating therapies and enhancing existing drugs to meet the needs of DMD patients. For instance, in March 2024, the U.S. FDA nodded Duvyzat (givinostat), an oral treatment for DMD, for patients aged six years and older.

The overall market is segregated into drug type, route of administration, and region.

Based on drug type, the DMD drugs market value from the gene therapy segment is estimated to grow at a significant rate from 2024 to 2032, driven by the urgent need to tackle the condition's genetic root. Gene therapies aim to correct or replace the faulty dystrophin gene, pivotal in muscle degeneration. Researchers are directly delivering functional dystrophin gene copies to muscle cells, employing advanced vectors for optimal gene transfer and expression.

Duchenne muscular dystrophy drugs industry from the injectable route of administration segment is anticipated to grow at a substantial CAGR through 2032 fueled by the rising demand for effective treatment delivery. Injectables offer direct access to muscle tissue or systemic circulation, enhancing drug absorption and efficacy. Moreover, advancements in injectable technologies are paving the way for efficient delivery systems, including sustained-release formulations and novel delivery methods.

Regionally, the Asia Pacific duchenne muscular dystrophy drugs market size is projected to witness a notable CAGR between 2024 and 2032, on account of the increasing collaborations among pharmaceutical companies, research institutions, and biotech firms. These partnerships, spanning clinical trials, drug development, and regulatory support, are set to enhance therapeutic options and outcomes for DMD patients in the region.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising disease burden of DMD
  - 3.2.1.2 Increased awareness and diagnosis of DMD
  - 3.2.1.3 Growing research funding and activities
  - 3.2.1.4 Advancements in genetic research
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High treatment costs
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Patent analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Exon skipping drugs
5.3 Corticosteroids
5.4 Gene therapy
5.5 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Injectable

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Spain
- 7.3.5 Italy
- 7.3.6 The Netherlands
- 7.3.7 Rest of Europe
7.4 Asia Pacific
- 7.4.1 Japan
- 7.4.2 China
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 South Korea
- 7.4.6 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Rest of Latin America
7.6 Middle East and Africa
- 7.6.1 Saudi Arabia
- 7.6.2 South Africa
- 7.6.3 UAE
- 7.6.4 Rest of Middle East and Africa